Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

3.9K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
3.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Role Of Notch Signalling In Intestinal Stem Cell Renewal01:12

Role Of Notch Signalling In Intestinal Stem Cell Renewal

2.1K
Notch signaling was first discovered in Drosophila melanogaster, where it is involved in cell lineage differentiation. Notch signaling regulates the maintenance and differentiation of intestinal stem cells or ISCs by controlling the expression of atonal homolog 1 or Atoh1. Atoh1 directs cells to differentiate into secretory cells.
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
2.1K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Intranasal Trans-Sialidase Vaccine Mitigates Acute and Chronic Pathology in a Preclinical Oral Chagas Disease Model.

Vaccines·2024
Same author

Synthesis of Structurally Related Coumarin Derivatives as Antiproliferative Agents.

ACS omega·2023
Same author

Synuclein Proteins in Cancer Development and Progression.

Biomolecules·2023
Same author

Allergic Sensitization Driving Immune Phenotyping and Disease Severity in a Mouse Model of Asthma.

Allergy, asthma & immunology research·2023
Same author

Rac1 as a Target to Treat Dysfunctions and Cancer of the Bladder.

Biomedicines·2022
Same author

The Endothelial Dysfunction Could Be a Cause of Heart Failure with Preserved Ejection Fraction Development in a Rat Model.

Oxidative medicine and cellular longevity·2022

相关实验视频

Updated: Jun 8, 2025

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.6K

克服结肠直肠癌治疗阻力:作为一种潜在的治疗方法,准Rac1信号通路.

Luciano E Anselmino1,2,3,4, Florencia Malizia1,2,3,4, Aylén Avila3,4

  • 1Instituto de Inmunología Clínica y Experimental de Rosario (IDICER, CONICET-UNR), Facultad de Ciencias Médicas (UNR), Rosario 2000, Argentina.

Cells
|November 8, 2024
PubMed
概括

对5-甲 (5-FU) 化疗耐药的结肠直肠癌 (CRC) 患者可能受益于向Rac1. 在临床前模型中,一种新的Rac1抑制剂1A-116恢复了5-FU敏感性,并抑制了瘤生长和转移.

关键词:
在Rac1Rac1中,我们可以使用Rac1Rac1.结肠直肠癌是什么意思重新定位重新定位.电阻的电阻是指电阻的电阻小型GTPases的使用.

更多相关视频

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.2K
Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer
06:19

Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer

Published on: July 18, 2017

9.9K

相关实验视频

Last Updated: Jun 8, 2025

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.6K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.2K
Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer
06:19

Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer

Published on: July 18, 2017

9.9K

科学领域:

  • 在瘤学瘤学.
  • 分子生物学分子生物学
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 结肠直肠癌 (CRC) 是全球癌症相关死亡的主要原因.
  • 5-甲 (5-FU) 是CRC的基石化疗,但耐药性是一个重大的临床挑战.
  • 了解5-FU抗性的机制对于开发有效的治疗策略至关重要.

研究的目的:

  • 为了阐明基底CRC耐药性和5FU治疗后复发的分子机制.
  • 确定新的治疗点和药物,以克服CRC中的5-FU耐药性.

主要方法:

  • 集成的in silico,in vitro和in vivo方法来研究5-FU耐药性.
  • 生物信息分析以确定差异表达的基因和丰富的途径.
  • 药物查以确定恢复5-FU敏感性的药物.
  • 在5-FU抗性CRC模型中对一种新型Rac1抑制剂 (1A-116) 的临床前评估.

主要成果:

  • 确定了与5-FU耐药性和复发相关的关键基因和途径.
  • 发现Rac1抑制剂1A-116在体外逆转了5-FU耐药性表型.
  • 证明1A-116在体内抑制瘤生长和转移.
  • 在1A-116治疗后,在耐药细胞中恢复了5-FU敏感性的证实.

结论:

  • 准细胞过程的关键调节者Rac1,是克服CRC中5-FU抗性的有希望的策略.
  • 新型Rac1抑制剂1A-116显示出作为对抗5-FU结直肠癌的治疗剂的潜力.
  • 对Rac1抑制的进一步研究可能会改善CRC患者的治疗结果.